{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T+Cell+Lymphoma&page=2", "query": { "condition": "T Cell Lymphoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T+Cell+Lymphoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T02:37:35.451Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02793544", "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Chronic Lymphocytic Leukemia (CLL)", "Chemotherapy-sensitive Lymphoma", "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma", "Acute Myelogenous Leukemia (AML)", "Acute Biphenotypic Leukemia (ABL)", "Acute Undifferentiated Leukemia (AUL)" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy on Day -1", "type": "RADIATION" }, { "name": "Infusion of non-T-cell depleted bone marrow on Day 0", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1", "type": "RADIATION" }, { "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -6 and -5", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -2 and -1", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -5 and -4", "type": "DRUG" }, { "name": "Post-HCT Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2016-12", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 11, "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793544" }, { "nct_id": "NCT03328104", "title": "Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "2 Years to 29 Years" }, "enrollment_count": 8, "start_date": "2018-07-24", "completion_date": "2023-06-29", "has_results": false, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03328104" }, { "nct_id": "NCT02477878", "title": "Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Lymphoma", "Multiple Myeloma", "Hematologic Neoplasms" ], "interventions": [ { "name": "BPX-501", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bellicum Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2016-07", "completion_date": "2033-01", "has_results": false, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Buffalo", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02477878" }, { "nct_id": "NCT05216835", "title": "Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Sabestomig (AZD7789)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "16 Years to 101 Years" }, "enrollment_count": 45, "start_date": "2022-03-18", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 5, "location_summary": "Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05216835" }, { "nct_id": "NCT04745234", "title": "Mogamulizumab Q4week Dosing in Participants With R/R CTCL", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T-Cell Lymphoma, Relapsed", "Cutaneous T-Cell Lymphoma Refractory" ], "interventions": [ { "name": "Mogamulizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-08-16", "completion_date": "2025-05", "has_results": false, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 7, "location_summary": "Duarte, California • Irvine, California • Stanford, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745234" }, { "nct_id": "NCT00002504", "title": "Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Hoag Memorial Hospital Presbyterian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1992-08", "completion_date": "1999-02", "has_results": false, "last_update_posted_date": "2011-05-12", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 5, "location_summary": "Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002504" }, { "nct_id": "NCT07049432", "title": "N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Non Hodgkin Lymphoma" ], "interventions": [ { "name": "N803", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2026-02", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07049432" }, { "nct_id": "NCT01163201", "title": "T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancy", "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia in Blast Crisis", "Anemia, Refractory, With Excess of Blasts", "Chronic Myeloproliferative Disease", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone B-cell Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle-Cell Lymphoma", "Prolymphocytic Lymphoma", "Large Cell Non-Hodgkin's Lymphoma", "Lymphoblastic Lymphoma", "Burkitt's Lymphoma", "High Grade Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Treg cells", "type": "BIOLOGICAL" }, { "name": "CD3+ Teff cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Umbilical cord blood transplantation", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2014-01", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01163201" }, { "nct_id": "NCT01142674", "title": "T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma, T-Cell, Peripheral" ], "interventions": [], "intervention_types": [], "sponsor": "Associazione Angela Serra per la ricerca sul cancro", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1650, "start_date": "2006-09", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2019-07-08", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 8, "location_summary": "Palo Alto, California • New Haven, Connecticut • St Louis, Missouri + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142674" }, { "nct_id": "NCT00064090", "title": "3-AP and Cytarabine in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "triapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vion Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-03", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-07-24T02:37:35.451Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064090" } ] }